A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT03505320
- Locations
- 🇫🇷
Site FR33003, Pessac, Nouvelle-Aquitaine, France
🇫🇷Site FR33002, Poitiers, Nouvelle-Aquitaine, France
🇫🇷Site FR33001, Brest, France
A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 566
- Registration Number
- NCT03504397
- Locations
- 🇺🇸
St. Jude Hospital Yorba Linda, Fullerton, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- Conditions
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT03474107
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇧🇪Site BE32013, Brussels, Belgium
🇧🇪Site BE32001, Gent, Belgium
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03421002
- Locations
- 🇮🇹
Site IT39002, Rome, Italy
🇮🇹Site IT39001, Rome, Italy
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT03409081
- Locations
- 🇮🇹
Site IT39001, Milan, Italy
🇦🇺Site AU61001, Canberra, Australia
🇬🇧Site UK44001, Birmingham, United Kingdom
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
- Conditions
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT03364153
- Locations
- 🇺🇸
Retina Specialty Institute, Pensacola, Florida, United States
🇺🇸Wilmer Eye Institute, Johns Hopkins, Baltimore, Maryland, United States
🇫🇷Centre ophtalmologique des Quinzes Vingts, Paris, France
A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03356639
- Locations
- 🇺🇸
Community Clinical Research, Austin, Texas, United States
🇺🇸Cctmg/Parexel, Glendale, California, United States
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 348
- Registration Number
- NCT03288545
- Locations
- 🇺🇸
Piedmont Cancer Institute, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT03260322
- Locations
- 🇮🇹
Site IT39005, Monza, Italy
🇮🇹Site IT39011, Negrar, Italy
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03241550
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University Hospital of Cleveland, Cleveland, Ohio, United States
🇺🇸Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States